Much progress has been made in the clinical, biological and technical aspects of the T-cell-depleted full-haplotype mismatched transplants for acute leukemia. Our experience demonstrates that infusing a megadose of extensively T-cell-depleted hematopoietic peripheral blood stem cells after an immuno-myeloablative conditioning regimen in acute leukemia patients ensures sustained engraftment with minimal graft-vs-host disease (GvHD) without the need of any post-transplant immunosuppressive treatment. Since our first successful pilot study, our efforts have concentrated on developing new conditioning regimens, optimizing the graft processing and improving the post-transplant immunological recovery. The results we have so far achieved in more than 200 high-risk acute leukemia patients show that haploidentical transplantation is now a clinical reality. Because virtually all patients in need of a hematopoietic stem cell transplant have a full-haplotype mismatched donor, who is immediately available, a T-cell depleted mismatched transplant should be offered, not as a last resort, but as a viable option to high risk acute leukemia patients who do not have, or cannot find, a matched donor.

Hematopoietic stem cell transplantation from alternative donors for high-risk acute leukemia: the haploidentical option / Aversa, Franco; A., Tabilio; A., Velardi; A., Terenzi; F., Falzetti; A., Carotti; T., Aloisi; M., Liga; M., Di Ianni; T., Zei; A., Santucci; Martelli, M. F.. - In: CURRENT STEM CELL RESEARCH & THERAPY. - ISSN 1574-888X. - 2:(2007), pp. 105-112.

Hematopoietic stem cell transplantation from alternative donors for high-risk acute leukemia: the haploidentical option.

AVERSA, Franco;
2007-01-01

Abstract

Much progress has been made in the clinical, biological and technical aspects of the T-cell-depleted full-haplotype mismatched transplants for acute leukemia. Our experience demonstrates that infusing a megadose of extensively T-cell-depleted hematopoietic peripheral blood stem cells after an immuno-myeloablative conditioning regimen in acute leukemia patients ensures sustained engraftment with minimal graft-vs-host disease (GvHD) without the need of any post-transplant immunosuppressive treatment. Since our first successful pilot study, our efforts have concentrated on developing new conditioning regimens, optimizing the graft processing and improving the post-transplant immunological recovery. The results we have so far achieved in more than 200 high-risk acute leukemia patients show that haploidentical transplantation is now a clinical reality. Because virtually all patients in need of a hematopoietic stem cell transplant have a full-haplotype mismatched donor, who is immediately available, a T-cell depleted mismatched transplant should be offered, not as a last resort, but as a viable option to high risk acute leukemia patients who do not have, or cannot find, a matched donor.
2007
Hematopoietic stem cell transplantation from alternative donors for high-risk acute leukemia: the haploidentical option / Aversa, Franco; A., Tabilio; A., Velardi; A., Terenzi; F., Falzetti; A., Carotti; T., Aloisi; M., Liga; M., Di Ianni; T., Zei; A., Santucci; Martelli, M. F.. - In: CURRENT STEM CELL RESEARCH & THERAPY. - ISSN 1574-888X. - 2:(2007), pp. 105-112.
File in questo prodotto:
File Dimensione Formato  
Aversa, Curr Stem Cell Ther 2007.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 443.17 kB
Formato Adobe PDF
443.17 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2438666
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 22
  • ???jsp.display-item.citation.isi??? ND
social impact